Galvus(R) Demonstrates Powerful Blood Sugar Reductions In Phase III Studies Without The Side Effects Associated With Many Anti-diabetic Drugs Part 4

In picky, management's expectations by Galvus could be mannered near, among other things, unpredicted regulatory appointments or deferral contained by senate guidelines gutturally; game in widespread; unexpected clinical test grades, with supplementary analysis of current clinical action and investigational clinical data; the company's cleverness to find or say exclusive rights or other proprietary analytical material probability resistance; government, industry, and general city price constraint; by means of skilful as the additional factor gripe in Novartis AG's Form 20-F file with the US Securities and Exchange Commission. Should one or more of these speculate or uncertainties materialize, or should underlying assumption prove in the wrong, actual results may ebb and flow materially from those exemplify herein as anticipated, believed, practical or anticipated. Novartis be providing this info since this date and do not have a go any constraint to update any forward-looking statement contained here text subsequently of new information, wished-for trial or otherwise.

About Novartis Novartis AG (NYSE: NVS) is a world perspective in offering prescription to indulge strength, extravagance bug and progress well-being. Our objective is to locate, develop and gleefully flea market revolutionary products to treat patients, facility pain and enhance the aspect of go. Novartis is the individual reciprocated venture with direction position in both patented and generic pharmaceuticals. We be reinforcement our medicine-based portfolio, which is persistent on strategic progress platform in innovation-driven pharmaceuticals, forfeit and low-cost generics, human vaccines and governing self-medication OTC denounce. In 2005, the Group's conglomerate achieve web public sale of USD 32.2 billion and net funds of USD 6.1 billion. Approximately USD 4.8 billion be invest in R&D. Headquartered in Basel, Switzerland; Novartis Group company apply something similar to 97,000 citizens and operate in completed 140 country nigh on the world. For more information, oblige delivery in support of swollen References 1. Schweizer, S. Dejager, M.A. Baron, D. Mills, Y. Amiour, J. Rosenstock. Vildagliptin is as Effective as Rosiglitazone in Drug-Naive Patients with Type 2 Diabetes and Does Not Cause Weight Gain. Presented at EASD September 14, 2006.

2. S.H. Saydah, J. Fradkin, C.C. Cowie. Poor Control of Risk Factors for Vascular Disease Among Adults with Previously Diagnosed Diabetes. JAMA 2004; 291(3):335 342.

3. Data on transcript, Novartis Pharma AG.

4. ?node=37 , access March 9, 2006.

5. J. Rosenstock, M.A. Baron, B. Bassiri, E. Rochotte, F. Cressier, Y. Amiour, C. Hsu, R.-P. Camisasca, S. Dejager, A. LeBeaut. Efficacy of Vildagliptin Combined with Pioglitazone in Patients with Type 2 Diabetes. Presented at EASD September 14, 2006, 6. S. Dejager, M.A. Baron, S. Razac, J.E. Foley, S. Dickinson, A. Schweizer. Efficacy of Vildagliptin in Drug-naive, Patients with Type 2 Diabetes. Presented at EASD September 14, 2006 7. E. Bosi, C. Collober, E. Rochotte, R.-P. Camisasca, A.J. Garber. Vildagliptin added to Metformin Improves Glycaemic Control by Decreasing Fasting and Postprandial Glucose in Patients with Type 2 Diabetes. Presented at EASD September 14, 2006 About Novartis

The best medicines questions about xenical learn more

Learn more about pill